Report Detail
Global (United States, European Union and China) Tardive Dyskinesia (TD) Treatment Market Research Report 2019-2025
- RnM3609102 |
- 22 July, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others.
In 2019, the market size of Tardive Dyskinesia (TD) Treatment is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Tardive Dyskinesia (TD) Treatment.
This report studies the global market size of Tardive Dyskinesia (TD) Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Tardive Dyskinesia (TD) Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Teva Pharma
Biogen
Johnson & Johnson
GlaxoSmithKline
Neurocrine Biosciences
Pfizer
Novartis
Sanofi
AstraZeneca
Bayer AG
Market Segment by Product Type
Valbenazine
Amantadine
Tetrabenazine
Clonazepam
Others
Market Segment by Application
Hospitals
Clinics
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Tardive Dyskinesia (TD) Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Tardive Dyskinesia (TD) Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Tardive Dyskinesia (TD) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Tardive Dyskinesia (TD) Treatment Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Valbenazine
- 1.3.3 Amantadine
- 1.3.4 Tetrabenazine
- 1.3.5 Clonazepam
- 1.3.6 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Tardive Dyskinesia (TD) Treatment Market Share by Application (2019-2025)
- 1.4.2 Hospitals
- 1.4.3 Clinics
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Tardive Dyskinesia (TD) Treatment Market Size
- 2.1.1 Global Tardive Dyskinesia (TD) Treatment Revenue 2014-2025
- 2.1.2 Global Tardive Dyskinesia (TD) Treatment Sales 2014-2025
- 2.2 Tardive Dyskinesia (TD) Treatment Growth Rate by Regions
- 2.2.1 Global Tardive Dyskinesia (TD) Treatment Sales by Regions 2014-2019
- 2.2.2 Global Tardive Dyskinesia (TD) Treatment Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Tardive Dyskinesia (TD) Treatment Sales by Manufacturers
- 3.1.1 Tardive Dyskinesia (TD) Treatment Sales by Manufacturers 2014-2019
- 3.1.2 Tardive Dyskinesia (TD) Treatment Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Tardive Dyskinesia (TD) Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Tardive Dyskinesia (TD) Treatment Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Tardive Dyskinesia (TD) Treatment Market Concentration Ratio (CR5 and HHI)
- 3.3 Tardive Dyskinesia (TD) Treatment Price by Manufacturers
- 3.4 Key Manufacturers Tardive Dyskinesia (TD) Treatment Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Tardive Dyskinesia (TD) Treatment Market
- 3.6 Key Manufacturers Tardive Dyskinesia (TD) Treatment Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Valbenazine Sales and Revenue (2014-2019)
- 4.1.2 Amantadine Sales and Revenue (2014-2019)
- 4.1.3 Tetrabenazine Sales and Revenue (2014-2019)
- 4.1.4 Clonazepam Sales and Revenue (2014-2019)
- 4.1.5 Others Sales and Revenue (2014-2019)
- 4.2 Global Tardive Dyskinesia (TD) Treatment Sales Market Share by Type
- 4.3 Global Tardive Dyskinesia (TD) Treatment Revenue Market Share by Type
- 4.4 Tardive Dyskinesia (TD) Treatment Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Tardive Dyskinesia (TD) Treatment Sales by Application
6 United States
- 6.1 United States Tardive Dyskinesia (TD) Treatment Breakdown Data by Company
- 6.2 United States Tardive Dyskinesia (TD) Treatment Breakdown Data by Type
- 6.3 United States Tardive Dyskinesia (TD) Treatment Breakdown Data by Application
7 European Union
- 7.1 European Union Tardive Dyskinesia (TD) Treatment Breakdown Data by Company
- 7.2 European Union Tardive Dyskinesia (TD) Treatment Breakdown Data by Type
- 7.3 European Union Tardive Dyskinesia (TD) Treatment Breakdown Data by Application
8 China
- 8.1 China Tardive Dyskinesia (TD) Treatment Breakdown Data by Company
- 8.2 China Tardive Dyskinesia (TD) Treatment Breakdown Data by Type
- 8.3 China Tardive Dyskinesia (TD) Treatment Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Tardive Dyskinesia (TD) Treatment Breakdown Data by Company
- 9.2 Rest of World Tardive Dyskinesia (TD) Treatment Breakdown Data by Type
- 9.3 Rest of World Tardive Dyskinesia (TD) Treatment Breakdown Data by Application
- 9.4 Rest of World Tardive Dyskinesia (TD) Treatment Breakdown Data by Countries
- 9.4.1 Rest of World Tardive Dyskinesia (TD) Treatment Sales by Countries
- 9.4.2 Rest of World Tardive Dyskinesia (TD) Treatment Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Teva Pharma
- 10.1.1 Teva Pharma Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.1.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.1.5 Teva Pharma Recent Development
- 10.2 Biogen
- 10.2.1 Biogen Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.2.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.2.5 Biogen Recent Development
- 10.3 Johnson & Johnson
- 10.3.1 Johnson & Johnson Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.3.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.3.5 Johnson & Johnson Recent Development
- 10.4 GlaxoSmithKline
- 10.4.1 GlaxoSmithKline Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.4.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.4.5 GlaxoSmithKline Recent Development
- 10.5 Neurocrine Biosciences
- 10.5.1 Neurocrine Biosciences Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.5.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.5.5 Neurocrine Biosciences Recent Development
- 10.6 Pfizer
- 10.6.1 Pfizer Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.6.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.6.5 Pfizer Recent Development
- 10.7 Novartis
- 10.7.1 Novartis Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.7.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.7.5 Novartis Recent Development
- 10.8 Sanofi
- 10.8.1 Sanofi Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.8.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.8.5 Sanofi Recent Development
- 10.9 AstraZeneca
- 10.9.1 AstraZeneca Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.9.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.9.5 AstraZeneca Recent Development
- 10.10 Bayer AG
- 10.10.1 Bayer AG Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Tardive Dyskinesia (TD) Treatment
- 10.10.4 Tardive Dyskinesia (TD) Treatment Product Introduction
- 10.10.5 Bayer AG Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Tardive Dyskinesia (TD) Treatment Sales Channels
- 11.2.2 Tardive Dyskinesia (TD) Treatment Distributors
- 11.3 Tardive Dyskinesia (TD) Treatment Customers
12 Market Forecast
- 12.1 Global Tardive Dyskinesia (TD) Treatment Sales and Revenue Forecast 2019-2025
- 12.2 Global Tardive Dyskinesia (TD) Treatment Sales Forecast by Type
- 12.3 Global Tardive Dyskinesia (TD) Treatment Sales Forecast by Application
- 12.4 Tardive Dyskinesia (TD) Treatment Forecast by Regions
- 12.4.1 Global Tardive Dyskinesia (TD) Treatment Sales Forecast by Regions 2019-2025
- 12.4.2 Global Tardive Dyskinesia (TD) Treatment Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Tardive Dyskinesia (TD) Treatment. Industry analysis & Market Report on Tardive Dyskinesia (TD) Treatment is a syndicated market report, published as Global (United States, European Union and China) Tardive Dyskinesia (TD) Treatment Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Tardive Dyskinesia (TD) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
